Lysaker, Norway
Lysaker, Norway

Time filter

Source Type

Patent
Pci Biotech As | Date: 2013-05-14

The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.


The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitising agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided.


Patent
Pci Biotech As | Date: 2013-03-15

The present invention provides an in vitro method of expressing an antigenic molecule or a part thereof on the surface of a dendritic cell using a PCI method with TPCS_(2a )at a concentration of 0.020-0.1 g/ml, using light of a wavelength of between 400 and 500 nm. Methods of treatment such as vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.


Patent
PCI Biotech AS | Date: 2012-07-05

The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.


Patent
PCI Biotech AS | Date: 2014-08-28

A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.


Patent
PCI Biotech AS | Date: 2014-08-28

A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patients skin. It has a retaining part for retaining the device in place over the region of the patients skin during an activation cycle. A light source is arranged to illuminate the patients skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.


News Article | February 28, 2017
Site: globenewswire.com

Oslo, 28 February 2017 - Please find enclosed the financial report and presentation for fourth quarter and preliminary full year 2016. CEO, Per Walday, comments: "It has been a transformative year for PCI Biotech, with promising signs of efficacy in the fimaChem Phase I bile duct cancer study, initiation of clinical Phase I for fimaVacc, and establishment of further high quality partnerships in the fimaNAc programme.  On the back of this progress, we also completed a fully underwritten rights issue of NOK 70 million that was more than 100% oversubscribed. The near term focus for the company is now to get regulatory clarity on the requirements for a marketing authorisation for fimaporfin in bile duct cancer and to complete the clinical translation of the promising preclinical results with fimaVacc". A presentation in English will be held today, Tuesday 28 February 2017, at Oslo Cancer Cluster Innovation Park. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=47521316), and it will be possible to post questions through the webcast console. PCI Biotech will additionally hold a presentation in Norwegian at Fondsfinans / Beringer Finance Oslo. Time: Tuesday February 28, 13:30pm - 14:30pm CET (local time). Venue: Haakon VII gate 2, Oslo If you wish to attend the presentation in Norwegian please confirm with an e-mail to ss@fondsfinans.no or stale.schmidt@beringerfinance.com. About PCI Biotech          PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For more information visit: www.pcibiotech.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | February 20, 2017
Site: globenewswire.com

Oslo, 20 February 2017 - PCI Biotech invites to a presentation of the company's fourth quarter 2016 report on Tuesday 28 February 2017 at Oslo Cancer Cluster Innovation Park. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=47521316), and it will be possible to post questions through the audiocast console. PCI Biotech will additionally hold a presentation in Norwegian at Fondsfinans / Beringer Finance Oslo. Time: Tuesday February 28, 13:30pm - 14:30pm CET (local time). Venue: Haakon VII gate 2, Oslo. If you wish to attend the presentation in Norwegian please confirm with an e-mail to ss@fondsfinans.no or stale.schmidt@beringerfinance.com. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 08am CET on 28 February 2017. For further information, please contact:


News Article | February 20, 2017
Site: globenewswire.com

Oslo, 20 February 2017 - PCI Biotech invites to a presentation of the company's fourth quarter 2016 report on Tuesday 28 February 2017 at Oslo Cancer Cluster Innovation Park. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=47521316), and it will be possible to post questions through the audiocast console. PCI Biotech will additionally hold a presentation in Norwegian at Fondsfinans / Beringer Finance Oslo. Time: Tuesday February 28, 13:30pm - 14:30pm CET (local time). Venue: Haakon VII gate 2, Oslo. If you wish to attend the presentation in Norwegian please confirm with an e-mail to ss@fondsfinans.no or stale.schmidt@beringerfinance.com. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 08am CET on 28 February 2017. For further information, please contact:


News Article | February 28, 2017
Site: globenewswire.com

Oslo, 28 February 2017 - Please find enclosed the financial report and presentation for fourth quarter and preliminary full year 2016. CEO, Per Walday, comments: "It has been a transformative year for PCI Biotech, with promising signs of efficacy in the fimaChem Phase I bile duct cancer study, initiation of clinical Phase I for fimaVacc, and establishment of further high quality partnerships in the fimaNAc programme.  On the back of this progress, we also completed a fully underwritten rights issue of NOK 70 million that was more than 100% oversubscribed. The near term focus for the company is now to get regulatory clarity on the requirements for a marketing authorisation for fimaporfin in bile duct cancer and to complete the clinical translation of the promising preclinical results with fimaVacc". A presentation in English will be held today, Tuesday 28 February 2017, at Oslo Cancer Cluster Innovation Park. The presentation can be followed as a live audiocast from Hegnar TV (http://webtv.hegnar.no/presentation.php?webcastId=47521316), and it will be possible to post questions through the webcast console. PCI Biotech will additionally hold a presentation in Norwegian at Fondsfinans / Beringer Finance Oslo. Time: Tuesday February 28, 13:30pm - 14:30pm CET (local time). Venue: Haakon VII gate 2, Oslo If you wish to attend the presentation in Norwegian please confirm with an e-mail to ss@fondsfinans.no or stale.schmidt@beringerfinance.com. About PCI Biotech          PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For more information visit: www.pcibiotech.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Loading PCI Biotech AS collaborators
Loading PCI Biotech AS collaborators